CD4 and lymphopenia: According to Japanese data, in our Italian case series of FL patients, we showed that the slightly higher risk of CMV reactivation in rituximab-treated patients could be linked to a more rapid lymphopenia and CD4 + T cell reduction, as G-BENDA regimen caused a deeper reduction in lymphocyte count after four cycles of therapy.